Available compounds per November 2024
–
| Drug | Target genes |
| Axitinib | KDR, FLT4 |
| Crizotinib | ALK, MET, MST1R, ROS1 |
| Dacomitinib | EGFR, HER2, HER4 |
| Erdafitinib | FGFR1, FGFR2, FGFR3, FGFR4 |
| Lorlatinib | ALK, ROS1 |
| Niraparib | BRCA1, BRCA2, RAD51C, RAD51D, PALB2, HRD-signature |
| Olaparib | ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD54L |
| Panitumumab | RAF/RAS wildtype |
| Sunitinib | CSF1R, FGFR1, FGFR2, FGFR3, FLT3, KDR, FLT4, KIT, PDGFRa, PDGFRb, RET |
| Talazoparib | ATM, ATR, FANCA, FANCC, FANCD2, FANCF, FANCM, RAD51, RAD51B, RAD54L, NBN, MRE11, BARD1, BRIP1, CHEK1, CHEK2, PALB2, RABAC1 (PRA1), HRD signature |
Onderstaand een overzicht van de geopende cohorten. Indien een geschikte patiënt zich voordoet die niet in een van deze cohorten past, kan er in overleg met het studieteam een nieuw cohort geopend worden.
| Drug | Tumor type | Target | Status |
| Abemaciclib | Esophageal | CCND3 amp | Closed |
| Abemaciclib | HNSCC | CCND1 amp | Closed |
| Abemaciclib | Melanoma | CCND1 amp | Closed |
| Abemaciclib | Ovarian | CCND1 amp | Closed |
| Abemaciclib | Prostate | CCND1 amp | Closed |
| Abemaciclib | Sarcoma | CDK4 amp | Closed |
| Abemaciclib | SCC bladder | CCND1 amp | Closed |
| Abemaciclib | Urachal cancer | CCND1 amp | Closed |
| Abemaciclib | Carcinoma of the small intestine | CCND3amp | Closed |
| Abemaciclib | Carcinoma of the small intestine | CDK4 amp | Closed |
| Abemaciclib | Urinary tract | CCND1 amp | Closed |
| Abemaciclib | Melanoma | CDK4 amp | Closed |
| Abemaciclib | CRC | CCND1 amp | Closed |
| Abemaciclib | NSCLC | CCND1 amp | Closed |
| Abemaciclib | NSCLC | CDK4ampl | Closed |
| Abemaciclib | Tumor agnostic cohort for CCND3ampl tumors (no CNS tumors) | CCND3amp | Closed |
| Abemaciclib | Astrocytoma | CCND1 amp | Closed |
| Abemaciclib | Glioblastoma | CDK4 amp | Closed |
| Abemaciclib | Tumor agnostic cohort for patients with CCND1 amplification (no CNS tumors) | CCND1amp | Closed |
| Abemaciclib | Tumor agnostic cohort for CDK4 ampl tumors (no CNS tumors) | CDK4ampl | Closed |
| Abemaciclib | Tumor agnostic cohort for CCND2amp tumors (no CNS tumors) | CCND2amp | Closed |
| Afatinib | NSCLC | NRG1 fusion | Closed |
| Alectinib | Tumor-agnostic | ALK fusion | Closed |
| Alectinib | Tumor-agnostic | ALK mut/amp | Closed |
| Alpelisib | Gynaecological tumors | AKT1 mut | Closed |
| Alpelisib | Miscellaneous tumors | PIK3CA mut | On hold |
| Alpelisib | Tumor-agnostic | Double hit | On hold |
| Alpelisib | Anal cancer | PIK3R2 mut | On hold |
| Alpelisib | Gynaecological tumors | PTEN loss | On hold |
| Alpelisib | Gynaecological SCC | PIK3CA mut | On hold |
| Alpelisib | Gynaecological PCC | PIK3CA mut | On hold |
| Alpelisib | HNSCC | PIK3Ca mut | On hold |
| Alpelisib | Prostate | PIK3CA mut | On hold |
| Alpelisib | Prostate | PTEN loss | On hold |
| Alpelisib | Renal cell | PTEN loss | On hold |
| Alpelisib | Salivary gland | PTEN loss | On hold |
| Alpelisib | Upper-GI | PIK3CA mut | On hold |
| Alpelisib | Radiation associated sarcoma/sarcomatoid carcinoom | PTENloss | On hold |
| Alpelisib | Cholangiocarcinoma | PTENloss | On hold |
| Alpelisib | Schildkliercarcinoom | PTEN loss | On hold |
| Alpelisib | GIST | PTEN loss | On hold |
| Alpelisib | Speekselkliercarcinoom | PIK3R1 | On hold |
| Atezolizumab + bevacizumab | Tumor-agnostic | TMB ≥16 mut/Mb | Closed |
| Axitinib | CRC | FLT1 amp | Closed |
| Axitinib | Solitary fibrous tumor | KDR mut | Open |
| Cabozantinib | Esophageal | MET mut | Closed |
| Cabozantinib | GIST | NTRK2 mut | Closed |
| Cabozantinib | Melanoma | MET amp | Closed |
| Cabozantinib | NSCLC | Ret fusion | Closed |
| Cabozantinib | Esophageal | RET mut | Closed |
| Cabozantinib | NSCLC | MET mut | Closed |
| Cabozantinib | Teratoma | MET amp | Closed |
| Crizotinib | NSCLC | MET mut | Closed |
| Crizotinib | ACUP | ALK fusion | Open |
| Crizotinib | Biliary tract | ALK mut | Open |
| Crizotinib | Colorectal | ALK mut | Open |
| Crizotinib | Colorectal | MET amp | Open |
| Crizotinib | Esophageal | MET amp | Open |
| Crizotinib | Gastric | MET amp | Open |
| Crizotinib | Inflammatory myofibroblastic tumor | ALK fusion | Open |
| Crizotinib | Hepatocellular | MET amp | Open |
| Crizotinib | NSCLC | MET amp | Open |
| Crizotinib | Thyroid | ALK mut | Open |
| Crizotinib | Thyroid | MET amp | Open |
| Crizotinib | Thyroid | MET fusion | Open |
| Crizotinib | Gynaecological tumors | MET amp | Open |
| Crizotinib | Sarcoma | ALK | Open |
| Crizotinib | Renal cell | MET mut | Open |
| Crizotinib | Pancreascarcinoom | ROS1 fusion | Open |
| Crizotinib | NSCLC | MET fusion | Open |
| Dabrafenib | Glioblastoma | BRAF V600 mut | Closed |
| Dabrafenib | Urinary tract | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | NSCLC | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Biliary tract | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | GIST | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Mamma | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Neuroendocrine carcinoma colon | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Pancreas | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Hairy Cell Leukemia | BRAF mut | Closed |
| Dabrafenib + trametinib | Glioblastoma | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Glioma (grade 3) | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Low grade glioma | BRAF V600 mut | Closed |
| Dacomitinib | Breast | HER2 mut | Open |
| Dacomitinib | Cervix | HER2 mut | Open |
| Dacomitinib | Vagina | HER2 mut | Open |
| Dacomitinib | Colorectal | EGFR amp | Open |
| Dacomitinib | Colorectal | HER2 amp | Open |
| Dacomitinib | Endometrial | HER2 amp | Open |
| Dacomitinib | Ampullary cancer | HER2ampl | Open |
| Dacomitinib | Endometrial | HER2 mut | Open |
| Dacomitinib | Esophageal | HER2 amp | Open |
| Dacomitinib | Gastric carcinoma | HER2 amp | Open |
| Dacomitinib | Gastro-esophageal junction | HER2 amp | Open |
| Dacomitinib | Pancreascarcinoom | HER2 amp | Open |
| Dacomitinib | Penile | HER2 fusion | Open |
| Dacomitinib | Penile | EGFR amp | Open |
| Dacomitinib | Urinary tract | EGFR amp | Open |
| Dacomitinib | Vulvar | EGFR ampl | Open |
| Dacomitinib | Esophageal | EGFR ampl | Open |
| Dacomitinib | Biliary tract | EGFR ampl | Open |
| Dacomitinib | Triple negative breast cancer | EGFR ampl | Open |
| Dacomitinib | Stomach cancer | HER2 amp | Open |
| Dacomitinib | Thyroid cancer | EGFR ampl | Open |
| Dacomitinib | UCC | HER2 mut | Open |
| Dacomitinib | NEC | HER2 mut | Open |
| Durvalumab | Tumor-agnostic | MSI | Closed |
| Entrectinib | Tumor-agnostic | ROS1 fusion | Closed |
| Erdafitinib | Porocarcinoom | FGFR1ampl | Open |
| Erdafitinib | Bijnierschorcarcinoom | FGFR3ampl | Open |
| Erdafitinib | Ameloblastoom | FGFR2mut | Open |
| Erdafitinib | Plexus choroidea carcinoma | FGFR2ampl | Open |
| Erdafitinib | CRC | FGFR1ampl | Open |
| Erdafitinib | Breast | FGFR1amp | Open |
| Erdafitinib | Pancreas | FGFR3ampl | Open |
| Erdafitinib | Prostate | FGFR3ampl | Open |
| Erdafitinib | NSCLC | FGFR1ampl | Open |
| Erdafitinib | Ovarian | FGFR1ampl | Open |
| Erdafitinib | CUP | FGFR1ampl | Open |
| Erdafitinib | Cholangiocarcinoma | FGFR2 mut | Open |
| Erdafitinib | Endometrial | FGFR1 ampl | Open |
| Erdafitinib | Cholangiocarcinoma | FGFR2 fusion | Open |
| Erdaftinib | NSCLC | FGFR3 fusion | Open |
| Erlotinib | Glioblastoma | EGFR fusion | Closed |
| Erlotinib | CRC | EGFR mut | Closed |
| Erlotinib | Glioblastoma | EGFR mut | Closed |
| Erlotinib | Anaplastic astrocytoma | EGFR mut | Closed |
| Lenvatinib | Adenoid cystic carcinoma | FGFR2 mut | Closed |
| Lenvatinib | ACUP | FGFR2 fusion | Closed |
| Lenvatinib | Anal cancer | FGFR3 mut | Closed |
| Lenvatinib | Anaplastic thyroid | FGFR3 mut | Closed |
| Lenvatinib | Ameloblastoma | FGFR2 mut | Closed |
| Lenvatinib | Biliary tract | FGFR2 fusion | Closed |
| Lenvatinib | Biliary tract | FGFR3 fusion | Closed |
| Lenvatinib | Biliary tract | FGFR2 mut | Closed |
| Lenvatinib | Biliary tract | FGFR3 mut | Closed |
| Lenvatinib | Cervix | FGFR3 mut | Closed |
| Lenvatinib | Colorectal | FGFR1 amp | Closed |
| Lenvatinib | Colorectal | FGFR2 amp | Closed |
| Lenvatinib | Endometrial | FGFR2 mut | Closed |
| Lenvatinib | Endometrial | FGFR3 amp | Closed |
| Lenvatinib | Esophageal | FGFR2 amp | Closed |
| Lenvatinib | Glioblastoma | FGFR3 fusion | Closed |
| Lenvatinib | Glioneural tumor | FGFR1 mut | Closed |
| Lenvatinib | Glioma | FGFR1 mut | Closed |
| Lenvatinib | HNSCC | FGFR3 mut | Closed |
| Lenvatinib | Breast | FGFR1 amp | Closed |
| Lenvatinib | Breast | FGFR2 amp/mut | Closed |
| Lenvatinib | Neuroendocrine nasal cavity | FGFR3 amp | Closed |
| Lenvatinib | NSCLC | FGFR1 amp | Closed |
| Lenvatinib | NSCLC | FGFR2 amp | Closed |
| Lenvatinib | Osteosarcoma | FGFR1 amp | Closed |
| Lenvatinib | Pancreas | FGFR1 amp | Closed |
| Lenvatinib | Pancreas | FGFR2 fusion | Closed |
| Lenvatinib | Papillary cancer | FGFR2 mut | Closed |
| Lenvatinib | Salivary gland | FGFR3 amp | Closed |
| Lenvatinib | Salivary duct | FGFR2 mut | Closed |
| Lenvatinib | Urachal cancer | FGFR2 amp | Closed |
| Lenvatinib | Urinary tract | FGFR3 mut | Closed |
| Lenvatinib | Vagina | FGFR3 mut | Closed |
| Lenvatinib | Glioblastoma | FGFR3 mut | Closed |
| Lenvatinib | Sarcoma | FGFR3 fusion | Closed |
| Lenvatinib | NSCLC | FGFR3 mut | Closed |
| Lorlatinib | NSCLC | ROS1 fusion | Open |
| Lorlatinib | Inflammatory myofibrolastic tumor | ALK fusion | Open |
| Lorlatinib | Cutaneous adnexal carcinoma | ROS-1 amp | Open |
| Lorlatinib | Mesenchymal tumor | ROS1 fusion | Open |
| Nilotinib | GIST | KIT mut | Closed |
| Nilotinib | Colorectal | PDGFRB amp | Closed |
| Nilotinib | Germ cell | KIT mut | Closed |
| Nilotinib | GIST | PDGFRA mut | Closed |
| Nilotinib | Melanoma | KIT mut | Closed |
| Nilotinib | Mesothelioma | PDGFRA mut | Closed |
| Niraparib | Tumor-agnostic | HRD | Open |
| Niraparib | Primairy brain tumors | HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) | Open |
| Niraparib | Lung cancer | HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) | Open |
| Niraparib | MPM | HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) | Open |
| Niraparib | All other tumor types | HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) | Open |
| Nivolumab | Tumor-agnostic | MSI (2nd stage) | Closed |
| Nivolumab | Tumor-agnostic | MSI (3rd stage) | Closed |
| Nivolumab | Tumor-agnostic | HML >450 | Closed |
| Nivolumab + ipilimumab | Tumor-agnostic | HML 200-1000 | Closed |
| Olaparib | Tumor-agnostic | BRCA mut/loss | Closed |
| Olaparib | Tumor-agnostic | ATM mut/loss | Closed |
| Olaparib | Tumor-agnostic | Other HRR alterations (breast, ovarian, prostate, pancreas, SCLC or stomach carcinoma) | Closed |
| Olaparib | Tumor-agnostic | Other HRR alterations (all other tumor types) | Open |
| Palbociclib | Colorectal | SMARCA4 mut | Closed |
| Palbociclib | Duodenal | CDKN2A loss/mut | Closed |
| Palbociclib | Endometrial carcinoma | CDKN2A loss/mut | Closed |
| Palbociclib | Esophageal | CDK4 amp | Closed |
| Palbociclib | Esophageal | CDKN2A loss/mut | Closed |
| Palbociclib | Glioblastoma | CDKN2A loss/mut | Closed |
| Palbociclib | HNSCC | CDKN2A loss/mut | Closed |
| Palbociclib | Melanoma | CCND1 amp | Closed |
| Palbociclib | Melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | Neuroendocrine tumor | CDKN2A loss/mut | Closed |
| Palbociclib | Neuroendocrine tumor | CCND1 amp | Closed |
| Palbociclib | NSCLC | CCND1 amp | Closed |
| Palbociclib | NSCLC | CDKN2A loss/mut | Closed |
| Palbociclib | (uvual) melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | Ovarian | CDKN2A loss/mut | Closed |
| Palbociclib | Ovarian | SMARCA4 mut | Closed |
| Palbociclib | Pancreas | CDKN2A loss/mut | Closed |
| Palbociclib | PECoom | CDK4 amp | Closed |
| Palbociclib | Primitive Neuro-ectodermal tumor | CDKN2A loss/mut | Closed |
| Palbociclib | Prostate | CDK4 amp | Closed |
| Palbociclib | Prostate | CDK6 amp | Closed |
| Palbociclib | Renal cell | CDKN2A loss/mut | Closed |
| Palbociclib | Sarcoma | CDK4 amp | Closed |
| Palbociclib | Vulva carcinoma | CDKN2A loss/mut | Closed |
| Palbociclib | Vulva carcinoma | CCND1 amp | Closed |
| Palbociclib | Astrocytoma | CDK4 amp | Closed |
| Palbociclib | Biliary tract | CDKN2A loss/mut | Closed |
| Palbociclib | Colorectal | CCND2 amp | Closed |
| Palbociclib | Colorectal | CDKN2A loss/mut | Closed |
| Panitumumab | Glioblastoma | BRAF-KRAS-NRAS wildtype | Closed |
| Panitumumab | Sarcoma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | ACUP | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Anal cancer | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Cervix | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Endometrial | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Gynaecological SCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | HNSCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Meningioma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | (uvual) melanoma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | NSCLC | BRAF-KRAS-NRAS wildtype + EGFR mut/amp | Open |
| Panitumumab | Salivary duct | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Thyroid | BRAF-KRAS-NRAS wildtype | Open |
| Pembrolizumab | Miscellaneous tumors | HML 140-290 | Closed |
| Pembrolizumab | Prostate | HML 140-290 | Closed |
| Pembrolizumab | Upper-GI | HML 140-290 | Closed |
| Pembrolizumab | Tumor-agnostic | HML > 290 | Closed |
| Pembrolizumab | Colorectal | HML 140-290 | Closed |
| Pembrolizumab | HNSCC | HML 140-290 | Closed |
| Pembrolizumab | Breast | HML 140-290 | Closed |
| Regorafenib | Adenoid cystic carcinoma | BRAF mut | Closed |
| Regorafenib | Duodenal | FLT1 amp | Closed |
| Regorafenib | Melanoma | KIT mut | Closed |
| Regorafenib | Esthesioneuroblastoma | RET | Closed |
| Regorafenib | NSCLC | RAF1 mut | Closed |
| Regorafenib | NSCLC | RET | Closed |
| Regorafenib | Thymus | KIT mut | Closed |
| Ribociclib | Anaplastic meningeoma | CDKN2A loss/mut | Closed |
| Ribociclib | ACUP | CDKN2A loss/mut | Closed |
| Ribociclib | Ceruminous adenocarcinoma | CDKN2A loss/mut | Closed |
| Ribociclib | Ependymoma | CDKN2A loss/mut | Closed |
| Ribociclib | Gastric cancer | CDKN2A loss/mut | Closed |
| Ribociclib | Melanoma | CDK4 amp | Closed |
| Ribociclib | Mesothelioma | CDKN2A loss/mut | Closed |
| Ribociclib | Mucoepidermoid | CDK6 amp | Closed |
| Ribociclib | Prostate | CDKN2A loss/mut | Closed |
| Ribociclib | Salivary gland | CDKN2A loss/mut | Closed |
| Ribociclib | Sarcoma | CDKN2A loss/mut | Closed |
| Ribociclib | Thymus | CDKN2A loss/mut | Closed |
| Ribociclib | Urinary tract | CDKN2A loss/mut | Closed |
| Rucaparib | Breast | HRR alterations | Closed |
| Rucaparib | Miscellaneous tumors | HRR alterations | Closed |
| Rucaparib | Ovarian | HRR alterations | Closed |
| Rucaparib | Pancreas | HRR alterations | Closed |
| Rucaparib | Prostate | HRR alterations | Closed |
| Sunitinib | Adenoid cystic carcinoma | PDGFRA amp | Open |
| Sunitinib | Colorectal | CSF1R mut | Open |
| Sunitinib | Colorectal | FLT3 amp | Open |
| Sunitinib | Breast | PDGFRB amp | Open |
| Sunitinib | Tumor-agnostic | Multi-hit | Open |
| Sunitinib | NSCLC | KIT amp | Open |
| Sunitinib | Osteosarcoma | PDFGRB mut | Open |
| Sunitinib | Ovarian | FGFR1 amp | Open |
| Sunitinib | Ovarian | FGFR2 amp | Open |
| Sunitinib | Pancreas | RET fusion | Open |
| Sunitinib | Pseudomyxoma peritonei | FLT3 mut | Open |
| Sunitinib | Prostate | KITmut | Open |
| Sunitinib | Prostate | PDFGRA mut | Open |
| Sunitinib | Thymus | KIT mut | Open |
| Sunitinib | Thyroid cancer | PDGFRB mut | Open |
| Sunitinib | Thyroid cancer | PDGFRA mut | Open |
| Sunitinib | Urinary tract | FGFR1 amp | Open |
| Sunitinib | Pseudomyxoma peritonei (PMP) | KIT mut | Open |
| Talazoparib | Tumor-agnostic | ATM/ATR alteraties | Open |
| Talazoparib | Tumor-agnostic | HRD signature | Open |
| Talazoparib | Tumor-agnostic | FANCA/FANCC/FANCD2/FANCF/FANC mut | Open |
| Talazoparib | Tumor-agnostic | other mutations in HRR genes (BARD1/BRIP1/CHECK1/2/PALB2/RABAC1(PRA1)) | Open |
| Trametinib | ACUP | MAP3K1mut | Closed |
| Trametinib | Cervix | MAP3K1mut | Closed |
| Trametinib | Cholangiocarcinoma | MAP2K4 mut | Closed |
| Trametinib | Colorectal | MAP2K4 mut | Closed |
| Trametinib | Breast | MAP3K1 mut | Closed |
| Trametinib | Breast | MAP2K4 mut | Closed |
| Trametinib | Neuroendocrine carcinoma | MAP3K1 mut | Closed |
| Trametinib | Ovarian | MAP2K4 mut | Closed |
| Trametinib | Pancreas | MAP2K4 mut | Closed |
| Trametinib | Prostate | MAP3K1 mut | Closed |
| Trametinib | Colorectal | MAP2K1 mut | Closed |
| Trametinib | Glioneural tumor | BRAF fusion | Closed |
| Trametinib | Histiocytair sarcoma | MAP2K1mut | Closed |
| Trametinib | Melanocytic tumor | GNA11 mut | Closed |
| Trametinib | NSCLC | BRAF mut | Closed |
| Trametinib | NSCLC | BRAF fusion | Closed |
| Trametinib | NSCLC | MAP2K1 mut | Closed |
| Trametinib | Ovarian | BRAF fusion | Closed |
| Trametinib | Pancreas | BRAF fusie | Closed |
| Trametinib | (Pilocytic) astrocytoma | BRAF fusion | Closed |
| Trametinib | Salivary duct | BRAF fusion | Closed |
| Trametinib | Tumor-agnostic | GNAS mut | Closed |
| Trametinib | Tumor-agnostic | NF1 mut | Closed |
| Trametinib | Tumor-agnostic | MAP2K1 mut | Closed |
| Trametinib | Urinary tract | BRAF fusion | Closed |
| Trametinib | Neuroendocrine carcinoma | NRAS mut | Closed |
| Trametinib | NSCLC | NRAS mut | Closed |
| Trametinib | Ovarian | NRAS mut | Closed |
| Trametinib | Pleimorph tumor | NRAS mut | Closed |
| Trametinib | Prostate | NRAS mut | Closed |
| Trametinib | Salivary duct | NRAS mut | Closed |
| Trametinib | Thyroid | NRAS mut | Closed |
| Trametinib | Yolk sac tumor | NRAS mut | Closed |
| Trametinib | Urethral carcinoma | NRAS mut | Closed |
| Trametinib | Cholangiocarcinoma | NRASmut | Closed |
| Trametinib | Tumor-agnostic | NRASmut | Closed |
| Trastuzumab + pertuzumab | Colorectal | HER2 amp | Closed |
| Trastuzumab + pertuzumab | NSCLC | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Adenoid cystic carcinoma | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Biliary tract | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Cervix | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Cervix | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Colorectal | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Duodenal | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Hidradenocarcinoma | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Melanoma | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Neuroendocrine carcinoma | HER2 amp | Closed |
| Trastuzumab + pertuzumab | NSCLC | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Ovarian | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Ovarian | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Salivary duct | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Urinary tract | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Urinary tract | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Vulva | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Goblet Cell Carcinoma | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Eccrien carcinoma | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Eccrien carcinoom | HER2 mutatie | Closed |
| Vemurafenib + cobimetinib | ACUP | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Biliary tract | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Erdheim Chester Disease | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | NSCLC | BRAF non-V600 mut | Closed |
| Vemurafenib + cobimetinib | Papillair craniopharyngeoma | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Prostate | BRAF non-V600 mut | Closed |
| Vemurafenib + cobimetinib | Thyroid | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Ovarian | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Salivary duct | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Sarcoma | BRAF V600 mut | Closed |
| Vismodegib | Sarcoma | PTCH1 mut | Closed |
| Vismodegib | CNS tumors | PTCH1 mut | Closed |
| Sunitinib | Breast cancer | FLT3 ampl | Open |
| Sunitinib | carcinosarcoma uterus | PDGFRA ampl | Open |
| Sunitinib | Prostate | KIT mut | Open |
| Sunitinb | NSCLC | FGFR1 ampl | Open |